FibroGen Inc (NASDAQ:FGEN) shares are moving higher in Monday’s after-hours session after the company announced the FDA cleared its Investigational New Drug (IND) for FG-3165. The company also announced a new clinical trial supply agreement with Regeneron.
What Happened: After the market close on Monday, FibroGen said the FDA cleared its IND of FG-3165, allowing the company to initiate a Phase 1 clinical trial.
FG-3165 is a galectin-9 targeted monoclonal antibody under development for treatment of solid tumors characterized by high Gal9 levels of expression. Phase 1 trials evaluating the safety ...